CSL Restricted CSLLY and uniQure Inc QURE introduced the four-year outcomes from the pivotal HOPE-B examine confirming the long-term sturdiness and security of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B sufferers.
The information confirmed that by way of 4 years, Hemgenix continues to ship elevated and sustained issue IX exercise ranges, can provide long-term and better bleed safety in comparison with prophylactic therapy, can get rid of the necessity for routine issue IX prophylaxis, and maintains a good security profile.
Additionally Learn: Why Is uniQure Inventory Skyrocketing On Tuesday?
Accepted in 2022 by the FDA, Hemgenix is the primary gene remedy for the therapy of adults with hemophilia B who presently use issue IX prophylaxis remedy, have present or historic life-threatening bleeding, or have repeated, severe spontaneous bleeding episodes.
It is usually the one authorised gene remedy for hemophilia B to deal with grownup sufferers with and with out AAV5-neutralizing antibodies.
Within the Part 3, open-label, single-dose, single-arm HOPE-B trial, 54 grownup male individuals with extreme or reasonably extreme hemophilia B, with or with out preexisting AAV5 neutralizing antibodies, had been infused with a single dose of Hemgenix.
Of the 54 individuals who acquired Hemgenix, 51 accomplished 4 years of follow-up. Hemgenix produced imply issue IX ranges of 41.5 IU/dL (n=50) at yr one, 36.7 IU/dL (n=50) at yr two, 38.6 IU/dL (n=48) at yr three and 37.4 IU/dL (n=47) at yr 4 post-infusion.
As well as, the imply adjusted annualized bleeding fee (ABR) for all bleeds was diminished by roughly 90% from lead-in as in comparison with yr 4.
Moreover, joint bleeds had been diminished from a imply ABR of two.34 at lead-in to 0.09 throughout yr 4. In yr 4, 94% of sufferers remained freed from steady prophylaxis therapy.
No sufferers returned to steady prophylaxis between yr three and yr 4.
There have been no severe opposed occasions associated to therapy.
Value Motion: QURE inventory is down 5.95% at $15.25 ultimately verify Friday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
